INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Waldencast plc and its officers or directors [1]. Financial Performance - On November 24, 2025, Waldencast reported its financial results for Q2 2025, revising its full-year 2025 net revenue outlook to be broadly in line with 2024, with an adjusted EBITDA margin expected in the high single digits [3]. - Previously, Waldencast had projected mid-teens net revenue growth and an adjusted EBITDA margin in the mid-to-high teens [3]. - The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million related to its Obagi Medical and Milk Makeup brands [3]. Market Reaction - Following the financial update, Waldencast's Class A ordinary share price decreased by $0.20, or 6.49%, closing at $2.88 per share on November 24, 2025 [4].